Key Dates
6 May 2008
Notification of Acceptances
26 May 2008
Early Registration Cut-off Date
9 June 2008
Late breaking Abstract Submission Date
2 July 2008
Pre & Post Congress Tours
2 July 2008
Social Program Bookings
2 July 2008
Congress Day Tours
9 July 2008
Accommodation Bookings
9 July 2008
Accommodation Deposit deadline
9-10 August 2008
Postgraduate Weekend Courses
10-14 August 2008
Congress Opens
With thanks to
Jerzy W. Kupiec-Weglinski, MD, Ph
Dr. Kupiec-Weglinski graduated from Warsaw Medical Academy in 1974, and received his Ph.D. at the Polish Academy of Sciences. In 1979 he joined the Transplant Research Laboratories, Brigham and Women’s Hospital at Harvard Medical School (HMS) in Boston, MA. Since 1997, Dr. Kupiec-Weglinski has been the Director of Dumont-UCLA Transplant Research Laboratories in Los Angeles, CA. He is Professor of Surgery and Pathology, and Vice-Chairman, Department of Surgery (Basic Research), at the David Geffen School of Medicine at UCLA. He holds the Joan S. and Ralph N. Goldwyn Endowed Chair in Immunobiology and Transplantation Research
Dr. Kupiec-Weglinski interests focus on the immunobiology of host sensitization, tolerance induction, regulatory T cells, ischemia and reperfusion injury. He has authored and co-authored over 370 papers. He is a member of the editorial board of Transplantation (since 1986), Liver Transplantation, Transplantation Immunology, Annals of Transplantation, among others. His research for the last 20 years has been continuously funded by NIH. Dr. Kupiec-Weglinski served as the member of the board of directors of American Society of Transplantation (AST), and in 2006, he received AST/Astellas Established Investigator Award in Basic Transplantation Research. He holds the Honorary Doctorate (“Honoris Causa”) from Medical Academy in Warsaw, and is the Foreign Member of Polish Academy of Sciences.
Prof Chistopher Parish
CHRISTOPHER R. PARISH PhD E2 Professor Division of Immunology & Genetics John Curtin School of Medical Research
Australian National University.
Professor Chris Parish received his undergraduate training at the University of Melbourne and then gained a PhD degree in immunology at The Walter & Eliza Hall Institute, Melbourne. Following postdoctoral positions at the ANU and the University of Oxford he returned to the John Curtin School of Medical Research and, until recently, was Head of the Division of Immunology and Genetics.
During the last 35 years Professor Parish has investigated various aspects of the immune system. During the early 1970's he was the first person to demonstrate that cell-mediated immunity and antibody formation are mutually antagonistic responses. This phenomenon, termed immune deviation, has recently been recognised as playing a critical role in the development of autoimmune disease and in resistance or susceptibility to different infections. Since the late 1970's Professor Parish has been particularly interested in the role that complex carbohydrates play in cell adhesion and cell migration. These studies have formed the theoretical basis for the development of a number of carbohydrate-based drugs that inhibit inflammation, tumour metastasis and angiogenesis. One of his carbohydrate-based drugs, PI-88, is expected to enter Phase III clinical trials in cancer patients in late 2007. His research findings also underpin several Australian biotechnology companies, such as Progen Pharmaceuticals, Biotron and Lipotek, that have a capital value of >$200m. He has published over 250 scientific papers and holds 23 international patents. In 2005 Prof Parish was awarded the Clive and Vera Ramaciotti Medal for Excellence in Biomedical Research in recognition of his scientific achievements.
Return to the State of The Art Program
